[{"Assets_0_Q3_USD":357149000.0,"CommonStockSharesOutstanding_0_Q3_shares":142301000.0,"EarningsPerShareBasic_1_Q3_USD":0.02,"EarningsPerShareBasic_3_Q3_USD":-0.45,"EarningsPerShareDiluted_1_Q3_USD":0.02,"EarningsPerShareDiluted_3_Q3_USD":-0.45,"NetIncomeLoss_1_Q3_USD":2749000.0,"NetIncomeLoss_3_Q3_USD":-60911000.0,"StockholdersEquity_0_Q3_USD":72389000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":143236000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":134633000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":141190000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":134633000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS INC","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20170930","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20171107"}]